HC Wainwright Reaffirms “Buy” Rating for Y-mAbs Therapeutics (NASDAQ:YMAB)

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $22.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 102.76% from the stock’s current price.

YMAB has been the subject of several other research reports. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th. Canaccord Genuity Group reiterated a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. BMO Capital Markets decreased their target price on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 13th. Finally, Morgan Stanley dropped their price objective on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating for the company in a research note on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.14.

Y-mAbs Therapeutics Stock Performance

YMAB traded down $0.74 during trading on Friday, hitting $10.85. The stock had a trading volume of 377,384 shares, compared to its average volume of 330,108. The stock has a 50 day simple moving average of $14.03 and a two-hundred day simple moving average of $13.12. Y-mAbs Therapeutics has a twelve month low of $5.04 and a twelve month high of $20.90. The company has a market capitalization of $485.97 million, a PE ratio of -20.09 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. During the same quarter in the previous year, the firm posted ($0.18) EPS. On average, equities research analysts anticipate that Y-mAbs Therapeutics will post -0.64 EPS for the current year.

Insiders Place Their Bets

In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of the company’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total value of $73,450.00. Following the completion of the transaction, the chief operating officer now owns 30,600 shares in the company, valued at $449,514. This represents a 14.04 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $12.97, for a total value of $389,100.00. Following the transaction, the insider now directly owns 67,681 shares in the company, valued at approximately $877,822.57. The trade was a 30.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 100,000 shares of company stock worth $1,338,100 in the last 90 days. Corporate insiders own 22.50% of the company’s stock.

Institutional Trading of Y-mAbs Therapeutics

A number of large investors have recently made changes to their positions in YMAB. Ameritas Investment Partners Inc. increased its stake in Y-mAbs Therapeutics by 39.9% in the first quarter. Ameritas Investment Partners Inc. now owns 3,701 shares of the company’s stock valued at $60,000 after purchasing an additional 1,056 shares during the period. Price T Rowe Associates Inc. MD increased its position in Y-mAbs Therapeutics by 8.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,158 shares of the company’s stock worth $345,000 after purchasing an additional 1,657 shares during the period. Caxton Associates LP acquired a new stake in shares of Y-mAbs Therapeutics in the 1st quarter valued at approximately $306,000. Boston Partners acquired a new position in Y-mAbs Therapeutics during the first quarter worth $556,000. Finally, Bank of New York Mellon Corp grew its stake in shares of Y-mAbs Therapeutics by 8.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after purchasing an additional 8,974 shares during the period. 70.85% of the stock is owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.